MedTrace Logo

Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma

NCT06405321 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2026-01-14

No results posted yet for this study

Summary

This multicenter retrospective study which included patients with hepatocellular carcinoma (HCC) who received conversion or neoadjuvant therapy to explore the best treatment options and the best benefit group.

Conditions

Interventions

DRUG

Conversion or neoadjuvant therapy.

Patients with hepatocellular carcinoma received conversion or neoadjuvant therapy.

Sponsors & Collaborators

  • Guangxi Medical University

    lead OTHER

Principal Investigators

  • Jian-Hong Zhong, Ph.D · Guangxi Medical University Cancer Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06405321 on ClinicalTrials.gov